Company Overview and News

 
Judges signal they'll revive Sarah Palin defamation lawsuit

12h nzherald.co.nz
NEW YORK (AP) — A federal appeals panel seems poised to reinstate a defamation lawsuit Sarah Palin brought against The New York Times after hearing oral arguments Friday.
NYTAB

2
Inside Facebook’s election War Room

12h sfgate
The War Room being built at Facebook’s headquarters in Menlo Park is part of its initiative to prevent political disinformation and election interference. It involves more than 300 people across the company.
FB NYTAB

 
Capitol Report: Rod Rosenstein discussed 25th Amendment to remove Trump and offered to wear a wire, report says

16h marketwatch
Deputy Attorney General Rod Rosenstein suggested secretly recording President Donald Trump and discussed recruiting cabinet members to invoke the 25th Amendment to remove him, the New York Times reported Friday.
NYTAB

 
Rosenstein suggested he secretly record Trump, discussed 25th Amendment: New York Times

17h marketwatch
Deputy Attorney General Rod Rosenstein suggested last year he secretly record President Donald Trump in the White House, the New York Times reported, and also discussed recruiting cabinet members to invoke the 25th Amendment to remove Trump from office. The Times' report said Rosenstein made these suggestions in the spring of 2017, when Trump's firing of then-FBI Director James Comey put the White House into turmoil.
NYTAB

 
Prefer to die on the beach than at work table in Alibaba: Jack Ma

19h moneycontrol
Jack Ma, the pioneer of China's internet industry, has termed the speculation swirling around his retirement as a "sea gossip", saying that he would rather die on the beach than in his executive office at Alibaba.
NYTAB

 
Tim Mullaney: Why the GOP fighting so hard for Kavanaugh

20h marketwatch
The Klown Kar Kavanaugh Karavan Keeps Kavorting through Washington, trying to salvage the Supreme Court seat for a nominee whose primary work experience, before becoming a federal judge, was working for the discredited independent-counsel investigation of President Bill Clinton and the discredited White House of George W. Bush.
NYTAB

3
This outperforming fund manager is ‘massively overweight’ emerging-markets stocks

20h marketwatch
Alex Umansky of the Baron Global Advantage Fund says growth in China and Brazil still trumps that of the U.S.
NYTAB PAGS

4
NY Times (NYT) Down in 3 Months: Is the Drop Momentary?

22h zacks
In spite of The New York Times Company’s (NYT - Free Report) concerted efforts to lower its dependency on traditional advertising and focus on digitalization, shares of this news and information provider have tumbled roughly 12.7% compared with the industry’s decline of 12% in the past three months. Analysts pointed that fall in advertising revenue both in print and digital coupled with sluggish growth in paid digital subscriber base during the second quarter of 2018 impacted the stock’s performance.
NWDVW MNI NYTAB NEWM

 
Kavanaugh’s Accuser Says She Would Testify under Right Terms

2018-09-21 thenationalherald
Protesters opposed to President Donald Trump's Supreme Court nominee, Brett Kavanaugh, demonstrate in the Hart Senate Office Building on Capitol Hill in Washington, Thursday, Sept. 20, 2018. (AP Photo/J. Scott Applewhite)
NYTAB

 
Isha Ambani-Anand Piramal destination engagement today; venue, theme, dress code and all you need to know

2018-09-21 freepressjournal.in
After a lavish engagement galore of Mukesh and Nita Ambani’s eldest son Akash with Shloka Mehta it is time for Isha and Anand Piramal to steal the limelight with their fairy-tale romance. Apparently, the couple have opted for an exotic location for their engagement ceremony.
NYTAB

 
Nikki Haley slams New York Times: ‘They knew the facts and released the story anyway’

2018-09-21 freepressjournal.in
Washington: Nikki Haley, the US Ambassador to the UN, on Thursday slammed The New York Times for publishing a wrong story about expensive curtains at her official residence despite knowing the actual facts.
NYTAB

 
PRESS DIGEST-New York Times business news - Sept 21

2018-09-21 reuters
Sept 21 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
NYTAB

 
The Wall Street Journal: Michael Cohen has reportedly talked about Trump to Mueller investigators

2018-09-21 marketwatch
Michael Cohen, President Donald Trump’s former lawyer, has met multiple times with special counsel Robert Mueller’s investigators, including within the past month, according to people familiar with the matter.
NYTAB

 
Outside the Box: Republicans’ response to Kavanaugh’s accuser shows what they really think of women

2018-09-20 marketwatch
When Supreme Court nominee Brett Kavanaugh was part of Ken Starr’s team investigating Bill Clinton, some Americans wondered how they could explain President Clinton’s behavior to children. That was a reasonable question to ask.
NYTAB

 
Danske Bank says billions may have been laundered at a single branch

2018-09-20 cnbc
COPENHAGEN — When a whistle-blower alleged that employees of a branch of the Danish lender Danske Bank had been knowingly working with customers who had broken the law, it was not the first time that questions had been raised about that particular office. It would not be the last.
NYTAB

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...